ZEUS Scientific, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

1976

Location

NJ US

Primary Industry

Medical Devices & Equipment

About

Based in New Jersey, US, and founded in 1976, ZEUS Scientific, Inc. operates as an In Vitro Diagnostic (IVD) company that designs and manufactures clinical diagnostic solutions. In October 2022, Sebia S.A., a global specialty diagnostic company and a portfolio company of CDPQ, CVC Capital Partners, and Tethys Invest, acquired ZEUS Scientific, LLC. As of October 2022, the company is led by its CEO Scott Tourville. ZEUS Scientific, Inc. focuses on the development, production, and marketing of Athena Multi-Lyte® test systems, ZEUS ELISA™ test systems, and ZEUS IFA™ test systems to detect autoimmune and infectious diseases. Its areas include inflammatory rheumatic diseases, serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology, and a number of infectious diseases, with a strong focus on Lyme disease.

Current Investors

Sebia S.A.

Request a demo to show more

Primary Industry

Medical Devices & Equipment

Sub Industries

Diagnostic Equipment, Medical Software, Application Integration Software, Analytics & Performance Software

Website

www.zeusscientific.com

Verticals

HealthTech, Manufacturing

Company Stage

Add-on

Total Amount Raised

Subscriber access only

Deals

Deals Type
Add-on

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	ZEUS Scientific, Inc.	11 Oct 2022

Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.